Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.
The guidance bump doesn't matter nearly as much as investors' response to the company's Q3 report suggests.
Johnson & Johnson (JNJ) has raised its sales outlook for fiscal 2026, with operating sales growth now projected to be between 6.4% and 6.8%, up from the previous range of 6.2% to 6.8%. However, the company's medical technology equipment division underperformed, with revenue growing by only 2.5% to $8.6 billion, below analysts' expectations of over $8.7 billion.
Despite this setback, J&J's overall sales and earnings guidance for the year remain robust. The company's medical tech division, which accounts for about one-third of its total sales and less than 20% of its adjusted net income, is not a significant liability. In fact, the orthopedics business within this division represents only about one-fourth of the medtech business.
More importantly, J&J is on track to become the leading cancer treatment company by 2030, with global oncology sales expected to reach $7.6 billion in Q3 alone, up over 16% from the previous year. The FDA recently granted a priority review to one of J&J's key oncology drugs, Rybrevant, further bolstering the company's growth prospects.
While the stock's recent volatility may deter some investors, the enduring strength of J&J's dividend and its long-term growth potential make it a compelling long-term investment.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
